EQS-Adhoc

Achiko AG: Achiko concludes Phase 1 study of Project Gumnuts for Covid-19 testing - Seite 2

The ongoing studies in Pekanbaru, Indonesia are being conducted with both the original prototype conjugate (Barcelona study) and additionally with a new conjugate with applied improvements. To date, over 250 patient tests have been compared with results obtained through nasopharyngeal swabs with 20 to 30 more being performed each week. Using prototyping materials, the Indonesian team has successfully replicated results from Spain in the field in Pekanbaru: test results from 64 participants initially yielded 82% sensitivity and 63% specificity rates. After conducting further testing using improved pre-production materials and further improvements in software and machine learning, sensitivity and specificity could be improved and testing time was reduced to under 15 minutes. The Company expects further gains to be made in ensuing months.

"We're now moving quickly to get the technology into test kits and into and through approvals, and we believe that given the progress beyond the initial prototypes, we'll be able to deliver test kits which pass the WHO guidelines for sensitivity and specificity", said Steven Goh, CEO of Achiko AG. "We believe that as testing moves from point of care to point of need, the presence of the right testing technologies with the right consumer experience, available in large quantities and at the right price point, to customers at the right time, will contribute to successfully responding to and overcoming the impact of Covid-19 on society and do good in this world. That is what we're here for."

About Achiko AG
We harness ground-breaking science with innovative technology to create solutions that provide a great user experience for patients, physicians and governing bodies alike, leading ultimately to the transformation of the healthcare industry.

The current development of our patent pending diagnostic testing kit for Covid-19 (Project Gumnuts) provides an easy and effective way that enables people to obtain the information they need and require. Complemented by our mobile check-in app (Teman Sehat), we empower users to manage their diagnostic experiences on their own terms, safeguard their privacy, share experiences, obtain passport verification and find community.